JP Morgan reiterates its Overweight rating on Vertex Pharmaceuticals VRTX following an update on VX-809 +Kalydeco Phase 2 study.
JP Morgan notes, "This morning, Vertex announced an update to the Phase 2 combination study of Vx-809 + Kalydeco in F508del cystic fibrosis (CF) patients. Specifically, Vertex
provided a correction to data previously provided (May 7) indicating that the absolute change in FEV1 was lower than previously reported. …We recommend purchase of VRTX on weakness today, as our thesis of lower combo pricing (~$75K) and low penetration (40%) still provides upside to the stock at current levels, but both of these assumptions seem unduly conservative."
VRTX closed at $64.85 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in